Citation Impact
Citing Papers
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
2007 StandoutNobel
Effects of inflammatory and anti‐inflammatory cytokines on the bone
2011
The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients
2006
A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis
2007
Fcγ receptors: structure, function and role as genetic risk factors in SLE
2009
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006 Standout
CD14lowCD16high: A cytokine‐producing monocyte subset which expands during human immunodeficiency virus infection
1995
Psoriasis
2009 Standout
Human Antibody Effector Function
1992
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.
1997
Pathogenesis and clinical features of psoriasis
2007 Standout
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
2008 Standout
Pathogenesis and therapy of psoriasis
2007 StandoutNature
Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction
2011
Juvenile idiopathic arthritis
2007 Standout
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept
2008
The changing landscape of atherosclerosis
2021 StandoutNature
Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease.
1998
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
2005 Standout
Temporal Aspects of Heparin-Induced Thrombocytopenia
2001 Standout
Psoriasis
2021 Standout
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Psoriasis: Which therapy for which patient
2018
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
2013
Osteoporosis: now and the future
2011 Standout
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
2006
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
2007 Standout
Super-Enhancers in the Control of Cell Identity and Disease
2013 Standout
The IL-23–IL-17 axis in inflammatory arthritis
2015
Clinical management of psoriatic arthritis
2018
Biology of Natural Killer Cells
1989 Standout
Function and heterogeneity of human Fc receptors for immunoglobulin G.
1989
Psoriasis
2015 Standout
A role of PIEZO1 in iron metabolism in mice and humans
2021 StandoutNobel
Genetic susceptibility to systemic lupus erythematosus in the genomic era
2010
Psoriasis: emerging therapeutic strategies
2005
Association Between FcγRIIa-R131 Allotype and Bacteremic Pneumococcal Pneumonia
2000
The development of allergic inflammation
2008 StandoutNature
Ankylosing spondylitis
2007 Standout
Evidence that cytokines play a role in rheumatoid arthritis
2008
Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis
2012
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
2005
The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro.
1992 StandoutNobel
PU.1 and Interferon Consensus Sequence-binding Protein Regulate the Myeloid Expression of the Human Toll-like Receptor 4 Gene
2000 StandoutNobel
Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
2009
Systemic Lupus Erythematosus
2011 Standout
Managing comorbid disease in patients with psoriasis
2010
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
2008
Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins
1991 Standout
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Inflammation in Hypertension
2020
Enhanced Phagocytosis through Inhibition of de Novo Ceramide Synthesis
2003 StandoutNobel
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis
2008
Measuring finger joint cartilage by ultrasound as a promising alternative to conventional radiograph imaging
2009
Rheumatoid arthritis
2010 Standout
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
2016
The genetics of human systemic lupus erythematosus
1998
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
2009
Future directions of bone-targeted therapy for metastatic breast cancer
2010
Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty‐two–week open‐label trial
2006
Mast-cell responses to pathogens
2004
Clinical targeting of the TNF and TNFR superfamilies
2013
The Fcγ Receptors on Human Macrophages
1989
Synovial mast cells: role in acute and chronic arthritis
2007
Idiopathic pulmonary fibrosis
2011 Standout
Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
1994 Standout
The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder
2006
Activation of platelets by sera containing igg1 heparin-dependent antibodies: an explanation for the predominance of the Fcγrlla “low responder” (his131) gene in patients with heparin-induced thrombocytopenia
1997
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Complement recruitment using bispecific diabodies
1997 StandoutNobel
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Fc receptor genes and the systemic lupus erythematosus diathesis
2007
Molecular Basis of Fc Receptor Function
1994
Impaired apoptosis, extended duration of immune responses, and a lupus-like autoimmune disease in IEX-1-transgenic mice
2002 StandoutNobel
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
1999 StandoutNobel
Osteoclasts and Arthritis
2009
Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells
2002 StandoutNobel
Knee osteoarthritis has doubled in prevalence since the mid-20th century
2017 Standout
The CD16+ (FcγRIII+) Subset of Human Monocytes Preferentially Becomes Migratory Dendritic Cells in a Model Tissue Setting
2002
Surface Phenotype Analysis of Human Monocyte to Macrophage Maturation
1990
Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1.
1991
A Common Dominant TLR5 Stop Codon Polymorphism Abolishes Flagellin Signaling and Is Associated with Susceptibility to Legionnaires' Disease
2003 StandoutNobel
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
2003 Standout
The Fc and not CD4 Receptor Mediates Antibody Enhancement of HIV Infection in Human Cells
1989 Science
The Engagement of Activating FcγRs Inhibits Primate Lentivirus Replication in Human Macrophages
2006 StandoutNobel
Markedly Different Pathogenicity of Four Immunoglobulin G Isotype-Switch Variants of an Antierythrocyte Autoantibody Is Based on Their Capacity to Interact in Vivo with the Low-Affinity Fcγ Receptor III
2000 StandoutNobel
Tolerogenic Dendritic Cells
2003 StandoutNobel
Human immunodeficiency virus 1 favors the persistence of infection by activating macrophages through TNF
2004 StandoutNobel
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
The role of calcium signaling in phagocytosis
2010
Osteoarthritis: an update with relevance for clinical practice
2011 Standout
Nod2 Deficiency Augments Th17 Responses and Exacerbates Autoimmune Arthritis
2018 StandoutNobel
JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis
2010 StandoutNobel
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
2008
Works of P A Ory being referenced
Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: Results from ADEPT
2005
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
2008
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial
2008
Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis
2010
Human Synovial Mast Cell Involvement in Rheumatoid Arthritis and Osteoarthritis. Relationship to Disease Type, Clinical Activity, and Antirheumatic Therapy
1991
A single amino acid distinguishes the high‐responder from the low‐responder form of Fc receptor II on human monocytes
1991
Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trial
2007
Denosumab‐mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients
2010
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
2005
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
2004
Radiography in the assessment of musculoskeletal conditions
2003
Characterization of polymorphic forms of Fc receptor III on human neutrophils.
1989
Psoriatic arthritis and imaging
2005
Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils.
1989
Molecular basis for a polymorphism involving Fc receptor II on human monocytes.
1989
CD16. Developmentally regulated IgG Fc receptors on cultured human monocytes.
1988
Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.
2006
An abnormality of the gene that encodes neutrophil Fc receptor III in a patient with systemic lupus erythematosus.
1990